HRP20110244T1 - Postupak liječenja raka - Google Patents
Postupak liječenja raka Download PDFInfo
- Publication number
- HRP20110244T1 HRP20110244T1 HR20110244T HRP20110244T HRP20110244T1 HR P20110244 T1 HRP20110244 T1 HR P20110244T1 HR 20110244 T HR20110244 T HR 20110244T HR P20110244 T HRP20110244 T HR P20110244T HR P20110244 T1 HRP20110244 T1 HR P20110244T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- compound
- sensitive
- use according
- susceptible
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 16
- 201000011510 cancer Diseases 0.000 title claims abstract 16
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 12
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 5
- 201000010881 cervical cancer Diseases 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Spoj formule (I): ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju osjetljivog raka, gdje se navedeni osjetljivi rak bira iz skupine koju čine rak jajnika i rak vrata maternice. Patent sadrži još 10 patentnih zahtjeva.
Claims (11)
1. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju osjetljivog raka, gdje se navedeni osjetljivi rak bira iz skupine koju čine rak jajnika i rak vrata maternice.
2. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni spoj je spoj formule (I')
[image]
3. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni spoj je spoj formule (I'')
[image]
4. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što osjetljivi rak je rak jajnika.
5. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što osjetljivi rak je rak vrata maternice.
6. Upotreba spoja kao što je definiran u patentnim zahtjevima 1-3 u proizvodnji medikamenta za liječenje osjetljivog raka, naznačena time što navedeni osjetljivi rak se bira iz skupine koju čine rak jajnika i rak vrata maternice.
7. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što osjetljivi rak je rak vrata maternice.
8. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što osjetljivi rak je rak jajnika.
9. Farmaceutski pripravak koji sadrži spoj kao što je definiran u patentnim zahtjevima 1-3, uz farmaceutski prihvatljivu podlogu, namijenjen upotrebi u liječenju raka osjetljivog na navedeni spoj, naznačen time što navedeni osjetljivi rak se bira iz skupine koju čine rak jajnika i rak vrata maternice.
10. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što osjetljivi rak je rak jajnika.
11. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što osjetljivi rak je rak vrata maternice.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74030805P | 2005-11-29 | 2005-11-29 | |
| PCT/US2006/045777 WO2007064753A2 (en) | 2005-11-29 | 2006-11-29 | Cancer treatment method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110244T1 true HRP20110244T1 (hr) | 2011-04-30 |
Family
ID=37847172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110244T HRP20110244T1 (hr) | 2005-11-29 | 2011-04-04 | Postupak liječenja raka |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090005406A1 (hr) |
| EP (2) | EP1954281B1 (hr) |
| JP (1) | JP2009517397A (hr) |
| AT (1) | ATE500831T1 (hr) |
| CY (1) | CY1111390T1 (hr) |
| DE (1) | DE602006020611D1 (hr) |
| DK (1) | DK1954281T3 (hr) |
| ES (1) | ES2359517T3 (hr) |
| HR (1) | HRP20110244T1 (hr) |
| PL (1) | PL1954281T3 (hr) |
| SI (1) | SI1954281T1 (hr) |
| WO (1) | WO2007064753A2 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2058307A1 (en) | 2007-11-12 | 2009-05-13 | Cellzome Ag | Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases |
| US20120197019A1 (en) * | 2009-10-23 | 2012-08-02 | Dharmesh Surendra Bhanushali | Compositions and processes |
| WO2011058179A1 (en) | 2009-11-16 | 2011-05-19 | Ratiopharm Gmbh | 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide |
| WO2011069053A1 (en) | 2009-12-04 | 2011-06-09 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl |
| JP5934229B2 (ja) | 2010-10-27 | 2016-06-15 | ノバルティス アーゲー | 眼血管疾患の処置のための投与計画 |
| US9278099B2 (en) * | 2011-10-31 | 2016-03-08 | Novartis Ag | Pazopanib formulation |
| JP2015507020A (ja) * | 2012-02-17 | 2015-03-05 | ファーマサイクリックス，インク． | ヒストンデアセチラーゼ阻害剤とパゾパニブの組み合わせおよびその使用 |
| CN103319410B (zh) * | 2012-03-22 | 2016-04-06 | 天津药物研究院 | 一种吲唑化合物的合成方法 |
| CN103232443B (zh) * | 2013-02-01 | 2014-12-10 | 天津药物研究院 | 一种吲唑衍生物的晶型及其制备和用途 |
| US10730859B2 (en) | 2013-11-05 | 2020-08-04 | Laurus Labs Limited | Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof |
| CN110878089A (zh) * | 2018-09-05 | 2020-03-13 | 江苏豪森药业集团有限公司 | 一种盐酸帕唑帕尼的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1307173C (zh) | 2000-12-21 | 2007-03-28 | 葛兰素集团有限公司 | 作为血管生成调节剂的嘧啶胺 |
| ES2236481T3 (es) | 2001-01-16 | 2005-07-16 | Glaxo Group Limited | Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer. |
| PL374963A1 (en) | 2002-06-17 | 2005-11-14 | Smithkline Beecham Corporation | Chemical process |
| WO2005105094A2 (en) * | 2004-04-16 | 2005-11-10 | Smithkline Beecham Corporation | Cancer treatment method |
-
2006
- 2006-11-29 EP EP06838636A patent/EP1954281B1/en active Active
- 2006-11-29 ES ES06838636T patent/ES2359517T3/es active Active
- 2006-11-29 EP EP10194774A patent/EP2380572A1/en not_active Withdrawn
- 2006-11-29 WO PCT/US2006/045777 patent/WO2007064753A2/en active Application Filing
- 2006-11-29 PL PL06838636T patent/PL1954281T3/pl unknown
- 2006-11-29 DK DK06838636.6T patent/DK1954281T3/da active
- 2006-11-29 JP JP2008542487A patent/JP2009517397A/ja active Pending
- 2006-11-29 SI SI200631005T patent/SI1954281T1/sl unknown
- 2006-11-29 US US12/094,687 patent/US20090005406A1/en not_active Abandoned
- 2006-11-29 AT AT06838636T patent/ATE500831T1/de active
- 2006-11-29 DE DE602006020611T patent/DE602006020611D1/de active Active
-
2011
- 2011-04-04 HR HR20110244T patent/HRP20110244T1/hr unknown
- 2011-04-18 CY CY20111100387T patent/CY1111390T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1111390T1 (el) | 2015-08-05 |
| WO2007064753A3 (en) | 2007-11-29 |
| US20090005406A1 (en) | 2009-01-01 |
| EP2380572A1 (en) | 2011-10-26 |
| DK1954281T3 (da) | 2011-05-16 |
| SI1954281T1 (sl) | 2011-06-30 |
| JP2009517397A (ja) | 2009-04-30 |
| DE602006020611D1 (de) | 2011-04-21 |
| PL1954281T3 (pl) | 2011-07-29 |
| EP1954281A2 (en) | 2008-08-13 |
| EP1954281B1 (en) | 2011-03-09 |
| ES2359517T3 (es) | 2011-05-24 |
| WO2007064753A2 (en) | 2007-06-07 |
| ATE500831T1 (de) | 2011-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110244T1 (hr) | Postupak liječenja raka | |
| JP6827092B2 (ja) | ルリコナゾール含有外用医薬組成物 | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| DE60228857D1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| HRP20090593T1 (hr) | Derivati benzimidazola i njihova uporaba kao antagonista aii receptora | |
| HRP20150744T4 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| MY138086A (en) | Novel urea derivative as vanilloid receptor-1 antagonist | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| PE20061373A1 (es) | Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida | |
| RS107504A (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use | |
| PT1227806E (pt) | Formulacao farmaceutica contendo tolterodina e sua utilizacao | |
| BR0003365A (pt) | Composições farmacêuticas | |
| BR0116605A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| WO2004032909A3 (en) | Stabilized pharmaceutical composition containing basic excipients | |
| AR056321A1 (es) | COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS | |
| HRP20170025T1 (hr) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| BRPI0407097A (pt) | Antagonista do casr | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| DK1383752T3 (da) | Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor |